CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.

MLA

Li, Hong, et al. “CD33-Targeted Lipid Nanoparticles (ACD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.” Molecular Pharmaceutics, vol. 12, no. 6, June 2015, pp. 2010–18. EBSCOhost, https://doi.org/10.1021/mp5008212.

APA

Li, H., Xu, S., Quan, J., Yung, B. C., Pang, J., Zhou, C., Cho, Y.-A., Zhang, M., Liu, S., Muthusamy, N., Chan, K. K., Byrd, J. C., Lee, L. J., Marcucci, G., & Lee, R. J. (2015). CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia. Molecular Pharmaceutics, 12(6), 2010–2018. https://doi.org/10.1021/mp5008212

Chicago

Li, Hong, Songlin Xu, Jishan Quan, Bryant C Yung, Jiuxia Pang, Chenguang Zhou, Young-Ah Cho, et al. 2015. “CD33-Targeted Lipid Nanoparticles (ACD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.” Molecular Pharmaceutics 12 (6): 2010–18. doi:10.1021/mp5008212.